Evidence map›Paper›PMID 30816013›Full record

Trial reportESC heart failure2019

Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.

Tetz C Lee, Min Qian, Lan Mu, Marco R Di Tullio, Susan Graham, Douglas L Mann, Koki Nakanishi, John R Teerlink, Gregory Y H Lip, Ronald S Freudenberger and 14 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 6 countries.

Tetz C LeeColumbia University Irving Medical Center, New York, NY, USA.
Min QianColumbia University Irving Medical Center, New York, NY, USA.
Lan MuColumbia University Irving Medical Center, New York, NY, USA.
Marco R Di TullioColumbia University Irving Medical Center, New York, NY, USA.
Susan GrahamThe State University of New York at Buffalo, Buffalo, NY, USA.
Douglas L MannWashington University School of Medicine, St. Louis, MO, USA.
Koki NakanishiColumbia University Irving Medical Center, New York, NY, USA.
John R TeerlinkSection of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Gregory Y H LipInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Ronald S FreudenbergerLehigh Valley Hospital, Allentown, PA, USA.
Ralph L SaccoThe University of Miami, Miami, FL, USA.
Jay P MohrColumbia University Irving Medical Center, New York, NY, USA.
Arthur J LabovitzThe University of South Florida, Tampa, FL, USA.
Piotr PonikowskiMilitary Hospital, Wroclaw, Wroclaw, Poland.
Dirk J LokDeventer Hospital, Deventer, The Netherlands.
Conrado EstolNeurological Center for Treatment and Rehabilitation, Buenos Aires, Argentina.
Stefan D AnkerDivision of Cardiology and Metabolism, Department of Cardiology; and Berlin-Brandenburg Center for Regenerative Therapies; Deutsches Zentrum für Herz-Kreislauf-Forschung partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Patrick M PullicinoKent Institute of Medicine and Health Science, Canterbury, UK.
Richard BuchsbaumColumbia University Irving Medical Center, New York, NY, USA.
Bruce LevinColumbia University Irving Medical Center, New York, NY, USA.
John L P ThompsonColumbia University Irving Medical Center, New York, NY, USA.
Shunichi HommaColumbia University Irving Medical Center, New York, NY, USA.
Siqin YeColumbia University Irving Medical Center, New York, NY, USA.
WARCEF Investigators
Columbia University Irving Medical Center · USBerlin-Brandenburger Centrum für Regenerative Therapien · DEBuffalo State University · USDeventer Ziekenhuis · NLInstituto de Neurología Cognitiva · ARLehigh Valley Hospital-Pocono · USMilitary Hospital · PKUniversity of Birmingham · GBUniversity of California, San Francisco · USUniversity of Kent · GBUniversity of Miami · USUniversity of South Florida · USWashington University in St. Louis · US

Funding

Warfarin vs. Aspirin in Reduced Ejection Fraction (WARCEF)U01NS043975 · NINDS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI HOMMA, SHUNICHI · 2001 to 2010
$43.3M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Warfarin vs Aspirin in Reduced Ejection Fraction -STATU01NS039143 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI THOMPSON, JOHN L · 2001 to 2010
$21.3M
Patient health information preference and statin therapyK23HL121144 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YE, SIQIN · 2014 to 2018
$784k
NCATS NIH HHS UL1 TR002548NHLBI NIH HHS K23-HL-121144NINDS NIH HHS U01-NS-039143NINDS NIH HHS U01-NS-043975
6 · The paper itself

Abstract

aimsThere is debate on whether the beneficial effect of implantable cardioverter-defibrillators (ICDs) is attenuated in patients with non-ischaemic cardiomyopathy (NICM). We assess whether any ICD benefit differs between patients with NICM and those with ischaemic cardiomyopathy (ICM), using data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. METHODS AND

resultsWe performed a post hoc analysis using WARCEF (N = 2293; ICM, n = 991 vs. NICM, n = 1302), where participants received optimal medical treatment. We developed stratified propensity scores for having an ICD at baseline using 41 demographic and clinical variables and created 1:2 propensity-matched cohorts separately for ICM patients with ICD (N = 223 with ICD; N = 446 matched) and NICM patients (N = 195 with ICD; N = 390 matched). We constructed a Cox proportional hazards model to assess the effect of ICD status on mortality for patients with ICM and those with NICM and tested the interaction between ICD status and aetiology of heart failure. During mean follow-up of 3.5 ± 1.8 years, 527 patients died. The presence of ICD was associated with a lower risk of all-cause death among those with ICM (hazard ratio: 0.640; 95% confidence interval: 0.448 to 0.915; P = 0.015) but not among those with NICM (hazard ratio: 0.984; 95% confidence interval: 0.641 to 1.509; P = 0.941). There was weak evidence of interaction between ICD status and the aetiology of heart failure (P = 0.131).

conclusionsThe presence of ICD is associated with a survival benefit in patients with ICM but not in those with NICM.

Indexed as

Defibrillators, ImplantablePropensity ScoreAgedAnticoagulantsAspirinCardiomyopathiesCause of DeathEchocardiographyFemaleFollow-Up StudiesHeart FailureHeart VentriclesHumansMaleMiddle AgedPlatelet Aggregation InhibitorsAnticoagulantsAspirinPlatelet Aggregation InhibitorsWarfarinHeart failure with reduced ejection fractionImplantable cardioverter-defibrillatorNon-ischaemic cardiomyopathyPropensity score matching

Identifiers

PMID30816013
PMCPMC6437435
OpenAlexW2918446862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.